Physician profile
Austin T Eagleton
NPI 1568753291
$996.45
in general payments reported to CMS, 2019-2025
14 companies · $93.28 in 2025
The $93.28 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $47.96 · 2021: $88.76 · 2022: $165 · 2023: $399 · 2024: $202 · 2025: $93.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $165.23 | 2022 | |
| Innovation Technologies INC | $149.77 | 2023 | Irrisept |
| Medtronic, INC. | $133.16 | 2023 | Ligasure |
| Teleflex LLC | $97.75 | 2024 | Quikclot |
| Davol INC. | $88.76 | 2021 | |
| Acera Surgical, INC. | $69.03 | 2024-2025 | Restrata Wound Matrix |
| Kci USA, INC. | $68.95 | 2023 | Prevena |
| Misonix INC | $47.96 | 2020 | |
| Polynovo North America LLC | $41.98 | 2024-2025 | Novosorb Btm |
| Integra Lifesciences Corporation | $31.80 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Vertex Pharmaceuticals Incorporated | $30.92 | 2025 | |
| Octapharma USA, INC. | $24.27 | 2025 | Fibryga |
| My01 INC. | $23.80 | 2023 | My01 Continuous Compartmental Pressure Monitor |
| Astrazeneca Pharmaceuticals LP | $23.07 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Eagleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.